L
ung cancer mortality has decreased considerably in the United States since the 1990s, but lung cancer remains the leading cause of cancer death, accounting for about 1 in 4 cancer deaths in 2017 (1) . Since the publication of the first Surgeon General's Report on smoking and health in 1964 (2), tobacco control programs and policies, including mass media campaigns, restrictions on youth access to tobacco, smoke-free air policies, and tobacco excise taxes, have been implemented in the United States. These efforts have reduced tobacco use and decreased smoking-related morbidity and mortality (3) (4) (5) (6) (7) (8) .
Although smoking and tobacco-related diseases are expected to continue to decrease, the precise effect that current tobacco control policies implemented since the 1960s will have on future smoking and tobacco-related outcomes is unknown. In particular, although the lung cancer burden in the United States is decreasing (9, 10) , it is unclear how long this will continue and at what rate. Improved knowledge of the future burden of lung cancer will aid in resource planning and evaluation and in assessing the potential effect of additional tobacco control efforts (such as regulations to reduce the nicotine levels of cigarettes [11] or raising the minimum age for legal purchase of tobacco products [12] ) and other cancer prevention strategies (such as lung cancer screening [13, 14] ).
Simulation models have been a valuable tool for quantifying the effect of tobacco control policies on future smoking trends in the United States (15) and worldwide (16) and projecting the effect of such efforts on smoking-related health outcomes (5, 6, 8) . For example, models have found that approximately 800 000 lung cancer deaths were averted among U.S. adults aged 30 to 84 years between 1975 and 2000 because of reduced tobacco smoking. However, this represents only 32% of lung cancer deaths that could have been avoided during that period (5) . Moreover, it has been estimated that about 8 million smoking-related deaths (including lung cancer deaths) were prevented from 1964 to 2012 due to tobacco control efforts (6) but that about 17.7 million persons still died prematurely during that period due to smoking. More recently, modeling analyses have suggested that raising the minimum 
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age for legal purchase of tobacco products would lead to substantial reductions in smoking-related mortality in the United States by 2100 (12) and that price-related tobacco control policies may greatly reduce deaths attributable to smoking, especially among low-socioeconomic status groups (17).
In this study, we applied 4 simulation models of smoking and the natural history of lung cancer to project lung cancer mortality in the United States from 1964 to 2065 and to estimate the corresponding annual attributable fraction of lung cancer deaths due to smoking. In the baseline scenario, we assumed that current patterns (trends) of decreasing rates of smoking initiation and intensity and increasing rates of smoking cessation by birth cohort would continue into the future (status quo trends scenario). We also performed sensitivity analyses with higher or lower future rates of smoking initiation, cessation, and intensity compared with the status quo. Projections of the future burden of smoking and lung cancer can serve as a point of reference as new developments take place that could influence risk, such as changes to patterns of lung cancer screening or increased use of e-cigarettes and other novel nicotine products. Future assessments of the effect of new prevention and treatment strategies require such status quo estimates as a basis for comparison.
METHODS
Models
Four models of the natural history of lung cancer were developed by investigators at 4 institutions within the Cancer Intervention and Surveillance Modeling Network (CISNET) lung cancer consortium (18): Georgetown University (GT), Massachusetts General Hospital and Harvard Medical School (MGH-HMS), the University of Michigan (UM), and Yale University (YU). The modeling groups collaborated closely to establish common model inputs and define model analyses and scenarios. Descriptions of each model are provided in the following sections and in the Supplement (available at Annals.org). We refer to them collectively as the CISNET-Lung models.
Smoking History Generator
The smoking history generator (SHG), which is based on the National Health Interview Survey (NHIS), the Cancer Prevention Study I (CPS-I) and II (CPS-II), and the Human Mortality Database, is a microsimulator that generates detailed individual smoking histories for the U.S. population (5, 19) and provides the following shared inputs for all CISNET-Lung models: rates of smoking initiation, smoking cessation, smoking consumption (cigarettes per day), and death from nonlung cancer causes (such as other cancer, cardiovascular disease, and chronic obstructive lung disease) by age, birth cohort, and sex ( Figure 1 of the Supplement) (5, 12, 19 -23 ). An earlier version of the SHG (19) was extended to consider NHIS data from 1964 to 2015. Smoking prevalence simulated with the SHG is consistent with that observed in the United States through 2016 ( Figure 1) (23, 24) .
Initial smoking cessation efforts are often not successful, with a high rate of relapse in the first 2 years after quitting (25, 26) . The SHG reclassified persons in the NHIS as current smokers at their reported age at quitting if they had quit smoking less than 2 years before the interview (about 13% of former smokers in the NHIS sample); otherwise, they were classified as former smokers. Thus, current smokers in the SHG included those who had quit within the past 2 years, and the probability of becoming a former smoker represented those who had not smoked for more than 2 years under the assumption of successful permanent cessation.
Projection of Smoking Patterns and Life Expectancy to 2065
Each CISNET-Lung model projected age-specific lung cancer mortality rates in the United States from 1964 to 2065 under specific smoking scenarios. For the status quo trends scenario, we assumed that current smoking patterns in the U.S. population (initiation, cessation, and intensity [cigarettes per day] by age, sex, year, and birth cohort) resulting from such factors as tobacco control efforts since the 1960s, tobacco industry promotion efforts, and the underlying susceptibility of the population would continue into the future. In this scenario, the SHG used smoking initiation, cessation, and intensity rates by birth cohort, age, and sex that were estimated from age-period-cohort models (23) fitted to the observed smoking patterns from the NHIS data from 1964 to 2015 ( Figure 2 of the Supplement). Figures 3 to 5 of the Supplement show the resulting age-specific smoking initiation, cessation, and intensity rates and smoking prevalence. We also projected life expectancy for women and men aged 40 years by using the Lee-Carter method to forecast age-specific mortality rates directly (without CISNET modeling) by smoking status, based on past and future smoking prevalence simulated by the SHG (12, 22, 27) (see the Supplement).
Sensitivity analyses considered 2 alternative scenarios: an optimistic scenario and a pessimistic scenario. For the optimistic scenario, we assumed 20% lower initiation rates, 20% higher cessation rates, and 20% lower mean intensities for future birth cohorts after 1997 compared with the rates in the status quo trends scenario. For the pessimistic scenario, we assumed 20% higher initiation rates, 20% lower cessation rates, and 20% higher mean intensities.
Smoking Dose-Response Module
Each CISNET-Lung model independently applied the SHG-simulated individual smoking history and age at death from causes other than lung cancer for the U.S. population in its own (smoking to lung cancer) doseresponse module to estimate annual age-specific lung cancer mortality as a function of smoking history, sex, and birth year. All models incorporated multiple factors characterizing a person's age-specific smoking history, such as age at smoking initiation, smoking intensity, and age at smoking cessation (for former smokers), and all models computed annual cross-sectional lung cancer mortality rates by sex, age, and smoking status.
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The MGH-HMS and UM models used individual SHG smoking histories as inputs to simulate individual lung cancer outcomes (microsimulation models), whereas the GT and YU models used aggregated cross-sectional smoking prevalence estimates by calendar year and age stratified by smoking status and sex to simulate populationlevel lung cancer rates (macrosimulation models).
The dose-response modules for the GT, UM, and YU models used a version of the two-stage clonal expansion (TSCE) model (28 -30) , a mechanistic model that is based on a biological paradigm of initiation, promotion, and progression of cell events during carcinogenesis and incorporates accumulation of genetic or epigenetic mutations in stem cells and clonal expansion of partially altered cells on the pathway to cancer (28, 29, (31) (32) (33) . Although these 3 models used the TSCE model as the dose-response module, each used it with a different parameterization: The GT model used parameters derived from fitting the TSCE model to the CPS-II data (28), whereas the UM and YU models used parameters obtained from fitting it to cohort data from the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) (29) . The MGH-HMS model used a set of logistic regression models and tumor progression functions calibrated to SEER (Surveillance, Epidemiology, and End Results) registry data, published cohort studies, and clinical trial data as the dose-response module (34, 35) . Brief descriptions of each model are provided in Table 1 , and more details are available in the Supplement.
Model Calibration and Validation
After first being calibrated to U.S. lung cancer mortality from 1969 to 2000, the CISNET-Lung models successfully reproduced observed lung cancer mortality from 2001 to 2010 ( Figure 6 of the Supplement). The models were further calibrated to match observed U.S. lung cancer mortality for 1969 to 2010 by incorporating multiplicative factors that adjusted for additional variation in lung cancer risk by year of death (period effects) 
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and year of birth (cohort effects) (36) . The UM and YU models adjusted for both period and cohort effects, and the GT and MGH-HMS models adjusted only for cohort effects. All models then projected their estimated period and/or cohort effects into the future to adjust their lung cancer mortality projections, thus indirectly accounting for factors and trends not directly captured in the models based solely on current and future smoking. The fully calibrated models were then used to project lung cancer mortality from 1964 to 2065. Additional details are provided in the Supplement.
Estimation of Population-Attributable Fraction
We used the simulated lung cancer mortality rates by smoking status to estimate or project the populationattributable fraction (PAF) of lung cancer mortality due to smoking from 1964 to 2065 (37) . The PAF measures the fraction of lung cancer deaths that could have been avoided if no smoking had occurred and is calculated for a given year as [Pr(lung cancer death) Ϫ Pr(lung cancer death | neversmokers)]/Pr(lung cancer death), where Pr(lung cancer death) denotes the average probability of lung cancer death among persons in the United States in that year and Pr(lung cancer death | never-smokers) denotes the probability of lung cancer death among never-smokers only.
Role of the Funding Source
This study was funded by grants U01CA152956 and U01CA199284 from the National Cancer Institute, which had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. Figure 1 shows smoking prevalence and its effect in the United States from 1964 to 2065 based on smoking histories simulated by the SHG. The top panel of Figure 1 shows observed smoking prevalence by sex among adults aged 18 to 84 years in the NHIS, as well as the SHG-projected prevalence of smoking under the status quo trends scenario from 1964 to 2065. The middle panel of Figure 1 shows the corresponding data and projections restricted to persons aged 30 to 84 years. The SHG simulations matched well with the U.S. prevalence observed in the NHIS from 1965 to 2016. Because recent birth cohorts have lower rates of smoking initiation and higher rates of cessation, the projections show that a status quo scenario for recent birth cohorts will result in decreasing annual prevalence as those from earlier cohorts with greater lifetime exposure to smoking die over time, at which point the prevalence will level off. When estimated directly by the Lee-Carter method (without a CISNET model) using current trends in the effect of smoking on lung cancer and non-lung cancer mortality and in life expectancy unrelated to smoking, the projected life expectancy at age 40 years ( Figure 1 
RESULTS
Lung Cancer Mortality Projections
Under the status quo trends scenario, all 4 CISNETLung models projected that lung cancer mortality in the United States would decrease considerably in the coming decades, with a rapid decrease until 2040 and a slower decrease thereafter. Figure 2 shows the mean age-adjusted lung cancer mortality rate (AAMR) per 100 000 persons across the models, with the shaded areas representing the range of estimates over the models. Model-specific results are shown in Figure 7 of the Supplement. Table 2 presents the AAMRs for selected years. The overall AAMR was 65.0 per 100 000 persons in 2015 (78.3 per 100 000 men and 54.2 per 100 000 women) and was projected to decrease to 13.9 per 100 000 persons in 2065 (13.4 per 100 000 men and 14.4 per 100 000 women). This represents a 79% overall decrease from 2015 to 2065, with a greater reduction in men (83% vs. 73%). Of note, the projected AAMRs for women and men were nearly equal by 2045. The mean number of lung cancer deaths across the models was 
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ORIGINAL RESEARCH about 135 000 in 2015 (74 000 in men and 61 000 in women) and was projected to decrease to about 50 300 in 2065 (23 400 in men and 26 900 in women). This represents an overall decrease of 63% (68% in men and 56% in women). Overall, the models projected that about 4.4 million lung cancer deaths (2.2 million in both men and women) will occur in the United States from 2015 to 2065. Figure 3 shows projections from the UM model of the population of persons aged 30 to 84 years and the corresponding number and proportion of lung cancer deaths by smoking status from 1964 to 2065 under the status quo scenario. Similar projections by sex are provided in Figures 9 and 10 of the Supplement, and projections from the other models are provided in Figures  11 to 14 of the Supplement. Qualitatively, all models consistently showed a decreasing proportion of lung cancer deaths among current smokers. For the UM model (Figure 3) , the percentage of lung cancer deaths among current smokers would be 17.4% (21.7% in men and 12.6% in women) in 2065, which represents a reduction of 52% (47% in men and 59% in women) compared with 2015. Despite the projected reductions in smoking prevalence, the simulations suggest that, under the status quo trends scenario, there will still be about 20 million smokers aged 30 to 84 years in the United States in 2065.
Sensitivity Analyses
The results under the more intensive (optimistic) and less intensive (pessimistic) tobacco control scenarios are provided in Figure 8 and Table 1 of the Supplement. Because these 2 alternative scenarios do not differ from the status quo trends scenario until the 1997 birth cohort, the differences in lung cancer outcomes are not apparent until later years. In the optimistic scenario, with lower initiation rates, higher cessation rates, and lower mean smoking intensities for future birth cohorts relative to the status quo scenario, the AAMR was projected to be 12.2 per 100 000 persons in 2065, which is about 12% lower than in the status quo scenario (13.9 per 100 000 persons), and the number of lung cancer deaths was projected to be 44 500 in 2065, which is about 11.7% lower than in the status quo scenario (50 400 deaths). In contrast, under the pessimistic scenario, the AAMR and the number of lung cancer deaths would be 16.0 per 100 000 persons and 58 200 in 2065, respectively, about 15.1% and 15.5% higher, respectively, than in the status quo scenario.
Population-Attributable Fraction
All models projected considerable decreases in the proportion of lung cancer deaths attributable to smoking (PAFs). Figure 4 shows the means (averaged across models) and ranges of the estimated PAFs from 1964 to 2065. The mean PAF was about 88% (range, 85% to 91%) for men and 79% (range, 70% to 86%) for women in 2015 and decreased to 58% (range, 49% to 68%) for men and 44% (range, 34% to 60%) for women in 2065.
DISCUSSION
Four independent models of the natural history of lung cancer were developed to project lung cancer mortality rates for U.S. men and women from 1964 (when the landmark Surgeon General's Report on smoking and health was published) to 2065. This analysis builds on our previous studies that estimated the number of lung cancer deaths (5) and tobacco-related deaths (6) prevented by tobacco control efforts in the United States during the first 50 years after publication of the Surgeon General's Report. 
Observed Predicted
Lines represent the mean age-adjusted lung cancer mortality rates across the 4 CISNET-Lung models, and the shaded areas show the ranges of age-adjusted lung cancer mortality rates per 100 000 persons across the models. Circles represent the observed U.S. lung cancer mortality rates for 1969 to 2010. The U.S. population in 2000 was used as the standard to calculate age-adjusted rates. An interactive version of the figure can be found at https://resources.cisnet.cancer.gov/projects/#shg/sbc2/tool?figure=fig_2. CISNET = Cancer Intervention and Surveillance Modeling Network.
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Although the 4 CISNET-Lung models had different structures and data sources, all of them accurately predicted the observed lung cancer mortality rates in the United States from 1969 to 2010. Under the status quo trends scenario, all models consistently projected considerable decreases in the lung cancer mortality rate between 2015 and 2065, with a concomitant reduction in the number of lung cancer deaths. Moreover, the results suggest that the existing disparities in lung cancer by sex will disappear by the mid-2040s, when lung cancer rates will become roughly equal between men and women. This reflects the convergence in smoking behaviors between men and women as current cohorts with similar smoking patterns by sex become the bulk of the smoking population.
The models projected a continued decrease in lung cancer mortality dating back to the 1990s. These projections assumed that current trends in smoking patterns (initiation, cessation, and intensity) would persist for future cohorts. As past cohorts with higher smoking rates (such as persons currently aged 54 years or older, who were born before the 1964 Surgeon General's Report on smoking) gradually die, smoking prevalence among adults aged 30 to 84 years will decrease from 19.7% in 2015 (21.6% in men and 17.8% in women) to 7.5% in 2065 (8.9% in men and 6.0% in women). The large reduction in lung cancer mortality during the next half-century will occur largely because of the lower initiation rates in current cohorts, leading to lower smoking prevalence at older ages, when lung cancer risk is greatest. All models projected considerable decreases in lung cancer mortality and the overall number of deaths from 2015 to 2065, even under the conservative assumptions in the status quo and pessimistic scenarios and despite the projected growth and aging of the U.S. population, as well as increases in life expectancy at age 40 years of about 6.7 and 5.5 years for men and women, respectively.
Despite these gains, the models projected that under the status quo trends scenario, around 4.4 million lung cancer deaths will still occur in the United States from 2015 to 2065. Most of these will be among ever-smokers, highlighting the need for additional efforts, such as lung cancer screening (13) , to further reduce the burden of lung cancer. In fact, the models project that in 2065, under the status quo scenario or even the optimistic or pessimistic scenarios, about 20 million persons aged 30 to 84 years will still be current smokers, indicating that tobacco use will continue to be a major public health problem through the next half-century.
This study was limited by status quo assumptions that did not explicitly consider the effects of changes in current smoking trends due to use of multiple products or changes in tobacco control efforts. For example, additional changes in smoking rates might be triggered by the changing landscape of tobacco products, such as the recent introduction of e-cigarettes (38, 39) and polytobacco use (40, 41) . However, many of these changes seem to be reflected in recent birth cohorts, which have shown dramatic reductions in smoking rates in recent years (42, 43) . These changes are also reflected in the recent decreases in smoking prevalence, which account for lower estimated initiation rates for recent years and cohorts. Moreover, given the lag between smoking exposure and lung cancer, changes that occur mostly among more recent cohorts are unlikely to affect lung cancer rates for at least 30 years. This future effect will depend on any effects of e-cigarette use on lung cancer, which are currently unknown. Similarly, major changes could also occur with the implementation of new tobacco control efforts, such as nicotine regulation (44) .
Our sensitivity analyses of optimistic and pessimistic scenarios captured changes that could affect younger cohorts, such as new product use or tobacco control interventions. We note that, although lung cancer screening is now being slowly adopted, changes to it could not only reduce lung cancer deaths but could also increase smoking cessation rates if support for quitting is combined with screening at the point of care (45). Our projections will need to be updated as new information becomes available on use of cigarettes and other tobacco products and adoption of screening. Another limitation is that the models for lung cancer mortality used only smoking history, age, and sex as risk factors without considering other factors, such as exposure to secondhand smoke, radon gas, asbestos, or other carcinogens; family history; chronic obstructive pulmonary disease; occupational exposures; race; and socioeconomic status (46 -51) . However, smoking is currently estimated to account for about 84% of lung cancer deaths in U.S. men and 81% in U.S. women (7), not including secondhand smoke, indicating that the overwhelming majority of lung cancer incidence and mortality is attributable to smoking. Moreover, our models accounted for age-specific risk for lung cancer among never-smokers, based on data from large prospective cohorts (28, 29, 52) . Although these models primarily account for age and sex, several studies have shown that there are no major time trends in lung cancer risk among never-smokers (53, 54), supporting our approach even in a future when most lung cancer cases will occur among nonsmokers. A third limitation is that the parameters built into each model's smoking dose-response module were estimated using specific cohort studies, such as the NHS, the HPFS, and the CPS-II, which may not be representative of the U.S. population. To address this, model results were calibrated to observed lung cancer mortality in the United States using period and/or cohort effects. These temporal effects were projected into the future to capture additional variations in lung cancer risk beyond smoking. Despite the use of different approaches to extrapolate these temporal adjustments across models, all estimates agreed well with observed lung cancer mortality in the United States and resulted in consistent projections of lung cancer deaths through 2065.
This study is strengthened by the fact that each model was validated and provided reasonable 10-year predictions after the last available year of survey data used for calibration. Moreover, the largely consistent results across models, despite their underlying differences, provide additional confidence in the projections through cross-validation (55). In addition, the models directly incorporated detailed smoking histories, enabling each to explicitly relate the complex dynamics of smoking initiation, cessation, and intensity rates by age, birth cohort, calendar year, and sex into the projections of lung cancer mortality.
The results of this study provide a status quo reference for comparison with future trends in smoking and lung cancer mortality that may accompany expanded tobacco control policies. Moreover, our approach of including multiple birth cohorts into model development provides a basis for assessing the potential of new tobacco control policies and other prevention strategies, such as lung cancer screening, among eligible persons in the entire U.S. population. Previous analyses by the CISNET lung group and the U.S. Preventive Services Task Force assessed the benefits and harms of lung cancer screening on the 1950 birth cohort (13, 14) . Further analyses will assess the effect on multiple U.S. birth cohorts and will focus on the effectiveness of screening for birth cohorts from more recent periods than the 1950s, which have had considerably less exposure to smoking. Furthermore, these models will serve as a basis for assessing the combined effect of tobacco control programs and lung cancer screening on lung cancer risk, particularly for smoking cessation programs implemented within the context of lung cancer screening (45).
In summary, our analyses indicate that maintaining existing tobacco control efforts will result in considerable reductions in the lung cancer burden in the United States. Our projections also highlight that smoking will continue to be an important determinant of lung cancer risk during this century. Continued policies and measures to discourage the uptake of smoking in youth and to promote cessation among current users are thus needed to retain the gains that have already been made, with additional efforts required to further decrease the toll of tobacco smoking on health. 
